Yang Ju, Liu Yue, Qu Chunna, Sun Jianbin, Li Tianying, Shi Lianjie
Department of Rheumatology and Immunology, Suining Central Hospital, Suining 629099, Sichuan, China.
Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Apr 18;57(2):388-392. doi: 10.19723/j.issn.1671-167X.2025.02.026.
Osteonecrosis of the mandible is also called avascular necrosis of the jaw, and it is a rare complication of bisphosphonates. It is characterized with pain, swelling, exposure of bone, local infection and pathologic fractures of the jaw. With the widespread usage of bisphosphonates in bone metastasis of malignant tumors and osteoporosis, this rare complication has received more attention in recent years. Here, we reported a case of bisphosphonates-related osteonecrosis of the jaw (BRONJ) caused by intravenous zoledronic acid for osteoporosis. A 62-year-old female patient with 7-year history of Sjögren's syndrome and 3-year history of osteoporosis developed BRONJ after 3-year treatment of zoledronic acid. Two months before she went to the Peking University International Hospital, she visited the dentist for periodontal purulent secretion and extracted one tooth from the right mandible. However, the condition was not improved and she felt persistent pain and swelling in the right mandible. Hence, she received repeated root curettage, but there was no improvement. Finally, she was diagnosed with osteonecrosis of the mandible based on the digital volume tomography scan, which showed right mandibular osteonecrosis bone destruction. She underwent surgical debridement of the necrotic bone and administered intravenous antibio-tics at the Peking University International Hospital. Histopathological analysis of the bone biopsy further confirmed the diagnosis of BRONJ. Her condition was improved successfully during a 3-year follow-up. Osteonecrosis of the mandible become more common with the increased use of bisphosphonates. Recent study has reported that osteonecrosis of the mandible is more likely to occur in patients with Sjögren's syndrome. In addition, age, long-term and irregular administration of glucocorticoids, irregular oral examination and treatment also might be the risk factors in the pathogenesis of osteonecrosis of the mandible. For the elder osteoporosis patients who would receive or had received bisphosphonate-related drugs, oral health status and the disease states associated with necrosis of the mandible such as Sjögren's syndrome should be comprehensively measured and fully evaluated during the whole process. Furthermore, to better understand and prevent or reduce the occurrence of this complication, we reviewed the patho-genesis, diagnosis, treatment, and prevention of BRONJ.
下颌骨坏死也称为颌骨缺血性坏死,是双膦酸盐类药物罕见的并发症。其特征为疼痛、肿胀、骨暴露、局部感染以及颌骨病理性骨折。随着双膦酸盐类药物在恶性肿瘤骨转移和骨质疏松症治疗中的广泛应用,这种罕见的并发症近年来受到了更多关注。在此,我们报告1例因静脉注射唑来膦酸治疗骨质疏松症导致的双膦酸盐类药物相关性颌骨坏死(BRONJ)病例。1例62岁女性患者,有7年干燥综合征病史和3年骨质疏松症病史,在接受唑来膦酸治疗3年后发生BRONJ。在前往北京大学国际医院就诊前2个月,她因牙周脓性分泌物就诊于牙医处,并拔除了右下颌1颗牙齿。然而,病情并未改善,她感到右下颌持续疼痛和肿胀。因此,她接受了多次根管刮治,但病情仍无改善。最终,根据数字容积断层扫描显示右下颌骨坏死性骨质破坏,她被诊断为下颌骨坏死。她在北京大学国际医院接受了坏死骨的手术清创,并静脉注射了抗生素。骨活检的组织病理学分析进一步证实了BRONJ的诊断。在3年的随访期间,她的病情成功得到改善。随着双膦酸盐类药物使用的增加,下颌骨坏死变得更为常见。最近的研究报告称,干燥综合征患者更易发生下颌骨坏死。此外,年龄、长期和不规律使用糖皮质激素、不规律的口腔检查和治疗也可能是下颌骨坏死发病机制中的危险因素。对于将要接受或已经接受双膦酸盐类相关药物治疗的老年骨质疏松症患者,在整个过程中应全面评估口腔健康状况以及与下颌骨坏死相关的疾病状态,如干燥综合征。此外,为了更好地理解并预防或减少这种并发症的发生,我们回顾了BRONJ的发病机制、诊断、治疗及预防。